Nanfang hospital, Southern Medical Uiversity
Guangzhou, Guangdong, 510080, China
Location status: Recruiting
NCT Number: NCT06500403
Patients treated with platinum-based chemotherapy drugs have the probability of developing PSVD. The diagnosis of PSVD depends on liver biopsy. In addition, the level of portal vein pressure has guiding value in the diagnosis and prognosis of PSVD. Many studies have shown that liver and spleen stiffness have high accuracy in diagnosis and prognosis. The purpose of this study is to evaluate the efficacy of the combination of liver and spleen stiffness in the diagnosis of PSVD and to search for effective biomarkers for the diagnosis of PSVD through a single-center, prospective, observational study.
Interested in participating?
Request Info18 year–80 year
All sexes
Observational
Guangzhou, Guangdong, 510080, China
Location status: Recruiting
PSVD is a supplement to non-cirrhotic portal hypertension and is defined as a class of diseases with characteristic pathological changes based on portal vein or hepatic sinuses abnormalities without cirrhosis. Some patients treated with platinum-based chemotherapy drugs will develop PSVD, which is clinically manifested as portal hypertension related complications. The diagnosis of PSVD depends on liver biopsy. In addition, the level of portal vein pressure has guiding value in the diagnosis and prognosis of PSVD. However, liver biopsy and pressure measurement are invasive methods. Many studies have shown that liver and spleen stiffness have high accuracy in diagnosis and prognosis. The purpose of this study is to evaluate the efficacy of the combination of liver and spleen stiffness in the diagnosis of PSVD and to search for effective biomarkers for the diagnosis of PSVD through a single-center, prospective, observational study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
liver and spleen stiffness measurement are non-invasive tools for evaluation of cirrhosis and portal hypertension
Time frame: 2 years
The sensitivity and specificity of the non-invasive models for the diagnosis of PSVD reached 85% and 60%, respectively
Time frame: 3 years
clinically significant ascites, esophagogastric variceal hemorrhage, hepatic encephalopathy, etc.
Time frame: 3 years
All-cause death
Time frame: 3 years
Patients underwent liver transplantation during follow up
Time frame: 3 years
Patients had accepted 3-year follow up
Contact information is provided by the study sponsor or research team.
Nanfang Hospital, Southern Medical University
Other
Noninvasive Tools for the Diagnosis of Porto-sinusoidal Vascular Disease: a Single-center, Prospective, Cohort Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05782556
Budd Chiari Syndrome, Budd-Chiari Syndrome
Freiburg im Breisgau, Germany
View Trial DetailsNCT07424963
Cirrhosis, Digestive System Diseases
Prague, Bohemia, Czechia
View Trial DetailsNCT04578301
Acute-On-Chronic Liver Failure, Digestive System Diseases
Bonn, Germany
View Trial DetailsNCT06145100
Common Variable Immunodeficiency, Immune System Diseases
Freiburg im Breisgau, Germany
View Trial Details